Xilio Therapeutics announced the hire of Stacey Davis to the role of chief business officer, where she’ll help spearhead the company’s corporate and business development strategy.
Davis comes to Xilio from Novartis Oncology, where she served as VP of U.S. Oncology, the company’s lung and immuno-oncology franchise. Prior to that, Davis worked as SVP and general manager at Prominex, as well as U.S. immunology, head, commercial strategy, insights and operations at Janssen Biotech.
“As an accomplished life science leader, Stacey brings significant strategic business experience building successful portfolios in oncology and immunology with an in-depth knowledge of the real-world patient and physician experience,” said Xilio president and CEO René Russo in a statement. “Her broad operational and business development experience coupled with her proven track record of leading organizations through critical development and corporate milestones, will be invaluable as we advance our pipeline and prepare for preliminary clinical data readouts anticipated later this year.”